Abe Yuki, Sato Takashi, Takagi Masaki, Watanabe Toru, Nagayama Yoshihisa, Hasegawa Tomonobu, Abe Tokinari
Department of Pediatrics, Niigata City General Hospital, Niigata, Japan.
J Pediatr Endocrinol Metab. 2012;25(5-6):587-90. doi: 10.1515/jpem-2011-0473.
Rabson-Mendenhall syndrome (RMS) is a genetic disorder characterized by severe insulin resistance and somatic characteristics. Recombinant insulin-like growth factor 1 (r-IGF-1) is used to treat RMS, as the IGF-1 and insulin receptors share homology. However, the effect of r-IGF-1 varies in patients and it is difficult to manage metabolic status appropriately in r-IGF-1 resistant cases. We report a Japanese boy with RMS who showed resistance to r-IGF-1 therapy and a novel mutation in the insulin receptor in the tyrosine kinase domain. Mutations in this region disturb tyrosine kinase catalytic activity in IGF-1 receptors as a result of dominant negative effects. We consider this mutation to be the cause of resistance to r-IGF-1. The patient also exhibited radiographical features of medullary sponge kidney and had severe nephrocalcinosis and hypokalemia, indicating Bartter syndrome. However, analysis revealed no mutations in the responsible genes and the etiology of the renal abnormalities therefore remains unknown.
拉布森 - 门登霍尔综合征(RMS)是一种遗传性疾病,其特征为严重的胰岛素抵抗和躯体特征。重组胰岛素样生长因子1(r-IGF-1)用于治疗RMS,因为IGF-1和胰岛素受体具有同源性。然而,r-IGF-1在患者中的疗效各不相同,在r-IGF-1抵抗的病例中,很难恰当地控制代谢状态。我们报告了一名患有RMS的日本男孩,他对r-IGF-1治疗有抵抗,并且在胰岛素受体的酪氨酸激酶结构域发现了一个新的突变。该区域的突变由于显性负效应而干扰了IGF-1受体中的酪氨酸激酶催化活性。我们认为这个突变是对r-IGF-1抵抗的原因。该患者还表现出髓质海绵肾的影像学特征,并有严重的肾钙质沉着症和低钾血症,提示巴特综合征。然而,分析显示相关基因没有突变,因此肾脏异常的病因仍然不明。